4.4 Article

Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty

期刊

DIGESTIVE DISEASES AND SCIENCES
卷 67, 期 2, 页码 622-628

出版社

SPRINGER
DOI: 10.1007/s10620-021-06990-8

关键词

Inflammatory bowel disease; Frailty; Function; Treatment; Anti-tumor necrosis factor

资金

  1. Crohn's and Colitis Foundation Career Development Award [568735]
  2. National Institutes of Health
  3. Crohn's and Colitis Foundation
  4. Chleck Family Foundation

向作者/读者索取更多资源

This study found that treatment response is a key factor in determining post-treatment frailty in IBD patients. Pre-treatment frailty and prior IBD-related hospitalization were independently predictive of higher likelihood of post-treatment frailty. Effective treatment of inflammatory states in older patients with IBD may improve frailty.
Background Frailty may be a risk factor for complications in inflammatory bowel diseases (IBD) patients. We examined the impact of treatment on IBD patients who were frail prior to treatment and identified predictors of post-treatment change in frailty. Methods In an electronic health record-based cohort of IBD patients initiating anti-tumor necrosis factor (TNF)-alpha agents, we applied a validated claims-based frailty index to determine frailty in the 1 year prior to and after treatment initiation. We characterized treatment non-response using a composite outcome of IBD-related hospitalization, surgery, change in therapy, or initiation of systemic steroids. We constructed multivariable logistic regression models to identify determinants of post-treatment frailty. Results The 1210 patients initiating anti-TNF therapy had a median age of 30 years; 20% were >= 50 years. In the first year after anti-TNF initiation, 40% were non-responders. Many more treatment non-responders were frail in the year following treatment compared with treatment responders (27% vs 7%, p < 0.001). Pre-treatment frailty (OR 2.01, 95% CI 1.35-3.00) and prior IBD-related hospitalization (OR 1.63, 95% CI 1.15-2.30) were independently predictive of higher likelihood of post-treatment frailty. Therapy response was associated with a lower likelihood (OR 0.24, 95% CI 0.16-0.34) of post-treatment frailty. Nearly 85% of patients who were frail prior to treatment demonstrated improvement in frailty following treatment Conclusions Response to anti-TNF therapy is an important determinant of post-treatment frailty in patients with IBD. Our findings suggest that effectively treating inflammatory states in older patients with IBD may improve frailty.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据